Literature DB >> 21140244

Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats.

Sernaz Uzunoglu1, Hakan Karagol, Fulya Ozpuyan, Rusen Cosar, Irfan Cicin, Vuslat Yurutcaloglu, Bengü Denizli, Özgür Tanriverdi, Necdet Sut, Zafer Kocak.   

Abstract

We aimed to compare the protective effect of L-carnitine (CAR) and amifostine (AMF) against cisplatin (CDDP)-induced nephrotoxicity through biochemical markers and histopathological evaluation. Fifty-seven Wistar albino male rats were randomly classified into six groups, which were AMF+CDDP (n = 11; 200 mg/kg AMF 30 min prior to 7 mg/kg CDDP), CAR+CDDP (n = 11; 300 mg/kg CAR 30 min prior to 7 mg/kg CDDP), CDDP (n = 11; 1 mL/kg isotonic saline 30 min prior to 7 mg/kg CDDP), AMF (n = 8; 200 mg/kg AMF alone), CAR (n = 8; 300 mg/kg CAR alone), and control (n = 8; 1 mL/kg isotonic saline alone). All drugs were given intraperitoneally. Five days after medication, animals were killed, and samples of blood and kidney tissues were collected for biochemical and histopathological evaluation. The serum urea level was highest in AMF+CDDP group among CDDP-applied groups without statistical significance (median, range: 88, 56-21 mg/dL; P > 0.05). There was no statistical significance among CDDP-applied groups in terms of creatinine level (P > 0.05). In the AMF+CDDP group, the median glomerular, tubular, and tubulointerstitial inflammatory damage scores were significantly higher than the other CDDP-applied groups (P < 0.001). The difference between CAR+CDDP and CDDP groups was not statistically significant in terms of renal damage scores. AMF+CDDP group had significantly higher median total nephrotoxicity score than all the other groups (P < 0.001). To conclude, AMF or CAR has no protective effect on CDDP-induced nephrotoxicity. Furthermore, our findings suggest that application of AMF before CDDP may enhance CDDP-induced nephrotoxicity histopathologically.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140244     DOI: 10.1007/s12032-010-9746-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.

Authors:  D Thomas Dickey; Y Jeffrey Wu; Leslie L Muldoon; Edward A Neuwelt
Journal:  J Pharmacol Exp Ther       Date:  2005-06-10       Impact factor: 4.030

2.  Use of amifostine in the therapy of osteosarcoma in children and adolescents.

Authors:  Antonio Sergio Petrilli; Delma Tostes Oliveira; Valeria Cortez Ginani; Rita Kechichian; Andrea Dishtchekenian; Werthon de Medeiros Roque Filho; Cristiana Tanaka; Carlo Gonçalves Dias; Maria do Rosário Dias de Oliveira Latorre; Algemir Lunardi Brunetto; Hedilene Cardoso; Maria Teresa Almeida; Beatriz de Camargo
Journal:  J Pediatr Hematol Oncol       Date:  2002 Mar-Apr       Impact factor: 1.289

3.  L-carnitine ameliorates gentamicin-induced renal injury in rats.

Authors:  Joel D Kopple; Hu Ding; Annamaria Letoha; Bela Ivanyi; David Pei-Yuan Qing; Lázló Dux; Hui-Yuan Wang; Sandor Sonkodi
Journal:  Nephrol Dial Transplant       Date:  2002-12       Impact factor: 5.992

4.  Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct.

Authors:  A C Seguro; M H Shimizu; L H Kudo; A dos Santos Rocha
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

5.  Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model.

Authors:  Mohamed M Sayed-Ahmed; Maha A Eissa; Sanaa A Kenawy; Nadia Mostafa; Menotti Calvani; Abdel-Moneim M Osman
Journal:  Chemotherapy       Date:  2004-09-03       Impact factor: 2.544

6.  Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats.

Authors:  Murat Caloglu; Vuslat Yurut-Caloglu; Gulay Durmus-Altun; Fulya Oz-Puyan; Funda Ustun; Rusen Cosar-Alas; Mert Saynak; Sule Parlar; Fatma N Turan; Cem Uzal
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-28       Impact factor: 2.557

Review 7.  Cisplatin and platinum drugs at the molecular level. (Review).

Authors:  Teni Boulikas; Maria Vougiouka
Journal:  Oncol Rep       Date:  2003 Nov-Dec       Impact factor: 3.906

Review 8.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

9.  Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells.

Authors:  Danyelle M Townsend; Mei Deng; Lei Zhang; Maia G Lapus; Marie H Hanigan
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

10.  Cisplatin nephrotoxicity and protection by milk thistle extract in rats.

Authors:  Gholamreza Karimi; Mohammad Ramezani; Zahra Tahoonian
Journal:  Evid Based Complement Alternat Med       Date:  2005-07-26       Impact factor: 2.629

View more
  5 in total

1.  Letter to the editor regarding the article by Uzunoglu et al.

Authors:  Yasemin Savranlar; Mehmet Fatih Sönmez
Journal:  Med Oncol       Date:  2012-09       Impact factor: 3.064

2.  Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study.

Authors:  T Aktoz; G Durmus-Altun; U Usta; N Torun; A Ergulen; I H Atakan
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

3.  Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury.

Authors:  Filiz Mercantepe; Tolga Mercantepe; Atilla Topcu; Adnan Yılmaz; Levent Tumkaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-02       Impact factor: 3.000

4.  Protective effects of amifostine on ischemia-reperfusion injury of rat kidneys.

Authors:  Ayse Arducoglu Merter; Burhan Mayir; Okan Erdogan; Taner Colak
Journal:  Indian J Pharmacol       Date:  2015 Mar-Apr       Impact factor: 1.200

5.  L-Carnitine Protection Against Cisplatin Nephrotoxicity In Rats: Comparison with Amifostin Using Quantitative Renal Tc 99m DMSA Uptake.

Authors:  Yakup Yürekli; Perihan Unak; Ciğdem Yenisey; Türkan Ertay; Fazilet Zumrut Biber Müftüler; Emin İlker Medine
Journal:  Mol Imaging Radionucl Ther       Date:  2011-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.